http://www.sanofi-synthelabous.com
Sanofi is a French multi-national health care corporation dedicated to developing novel and innovative therapeutic agents for a wide range of clinical disorders. Xaliproden is an original Sanofi compound which exhibits neurotrophic and neuroprotective effects. It is being developed primarily as a potential treatment for ALS. Xaliproden is a nonpeptide compound that possesses neurotrophin-like activity. The compound reduces the histological (tissue), neurochemical and functional deficiencies produced in widely divergent models of experimental neurodegeneration. The ability of Xaliproden to increase the innervation of human muscle cells by spinal cord explants and to prolong the survival of mice suffering from progressive motor neuronopathy suggests the compound might be an effective therapy for the treatment of ALS. Even though the mechanism by which Xaliproden produces its neurotrophic and neuroprotective effects is not fully understood, it is thought to be related to the compound's ability to mimic the activity or stimulate the biosynthesis of a number of neurotrophins (such as NGF and BDNF) originating within the body.
Novactyl is a privately held pharmaceutical company. Its proprietary technology platform is based on a family of small molecule compounds called pyridine carboxylates. Certain pyridine carboxylates have been shown to disrupt Zinc Finger Proteins (ZFP), which are essential proteins involved in various infectious and proliferative disorders. ZFPs represent a therapeutic target that is distinct from that of the traditional anti-viral and anti-cancer agents. They have been identified by the National Cancer Institute as critical therapeutic targets in the treatment of viral and cell growth disorders. In the near-term, Novactyl is focusing on the evaluation of the dermatologic (acne), ophthalmic (adenovirus and herpes eye infections), and topical anti-viral (herpes labialis-cold sores, and herpes genitalis-genital herpes) applications of its technology. Longer term development plans include the evaluation of various systemic applications of pyridine carboxylate derivatives in virology (Hepatitis B and C), CNS (Alzheimer's) and oncology. The Company owns six issued patents, one allowed patent application and four pending applications in the US, as well as several pending foreign applications. These patents contain both pharmaceutical composition and method of treatment claims for these products and their derivatives. At present, the Company's technology platform has produced two drug candidates with attractive profiles, PCL-016 and its derivative, FSR-488. Novactyl's development strategy has been to reach value points through the pursuit of topical indications (herpes and acne) for its lead compound, PCL-016. This provides the faster route to regulatory approval and commercial revenues. The Company is also currently assessing the potential ophthalmic applications for its technology. Novactyl plans to generate initial revenues by licensing the further development and commercialization of certain of its products. Novactyl intends to retain selected product indications for internal development and marketing. The activity of PCL-016, Novactyl's lead product, has been assessed in various pre-clinical studies. It has been shown to be an anti-viral agent in both cell culture and animal testing with a potentially broad activity against a wide variety of ZFP-carrying viruses. It combines a distinct anti-viral site of action with immuno-stimulatory activity. PCL-016 was also shown to be active against P. acnes, the bacteria involved in the development of acne vulgaris. Initial pre-clinical studies of FSR-488, Novactyl's "second generation" product, have shown it to be significantly more potent than PCL-016. Further derivatives of these lead products are being evaluated in the Novactyl development program. Novactyl currently has two active Investigational New Drug applications (INDs) with the FDA for the evaluation of PCL-016 in herpes labialis (cold sores) and in mild to moderate acne. A Phase I topical safety study was completed successfully. Novactyl started Phase II clinical testing of PCL-016 on acne patients in 2002. Novactyl has granted a license to Upsher-Smith Laboratories for the development and commercialization of PCL-016 and FSR-488 for the topical treatment of herpes labialis (cold sores) and herpes genitalis. A Phase II clinical program evaluating the efficacy of PCL-016 in these indications will begin shortly under the direction of our licensing partner. Novactyl was founded in January, 2000 and is incorporated in the State of Delaware. Novactyl is headquartered in St. Louis, Missouri.
Wex Pharmaceuticals Inc. (WEX) is engaged in the discovery, development, manufacture and commercialization of drug products for the management of pain. The Company’s platform technology is build upto Tetrodotoxin (TTX), a naturally occurring sodium channel blocking compound found primarily in the puffer fish or blowish. In addition the Company owns and operates a drug manufacturing facility in Nanning, China. This facility manufactures TTX for use by it in its clinical trials. (Source: ARS)
Liponex is a biopharmaceutical company moving into Phase II trials with CRD5, its lead candidate. CRD5 raises High Density Lipoprotein (HDL), often called "good cholesterol". Novel HDL therapies, such as CRD5, are an area of significant interest for pharmaceutical companies worldwide. Liponex also has a broad pipeline of products with drug candidates in areas such as atherosclerosis, cancer, and infectious disease. The goal of Liponex is to continue to develop our proprietary technologies to fight human disease. Our mission is to derive value for our shareholders by developing our drug candidates and programs to the point where there is potential for licensing opportunities. Our strategy to achieve these objectives includes: Advancing CRD5 through Phase II clinical trials Developing innovative therapeutics from our proprietary technologies, with the intent of seeking licensing opportunities or partnerships for later stage development and commercialization. Advancing our product pipeline into additional therapeutic areas Maintaining a strong strategic protection and expansion of our intellectual property to ensure a competitive position in the marketplace and value to our stakeholders. Liponex Inc was established in 2000 based on discoveries made by Dr. Daniel Sparks at the University of Ottawa Heart Institute. In September 2005 Liponex completed a successful IPO and is now traded on the Toronto Stock Exchange under the symbol 'LPX'. Liponex is addressing unmet needs in the world's largest pharmaceutical markets.
Resverlogix Corp. is a Canadian biotechnology company engaged in the discovery and development of pharmaceuticals. It has developed three separate programs in the cardiovascular disease (CVD) area of research. The primary CVD program is NexVas Plaque Regression (NexVas PR), which targets ApoA-I enhancement via small molecules for plaque stabilization and regression. ApoA-I is the key building block of lipoprotein (HDL), the good cholesterol. NexVas Vascular Inflammation (NexVas VI), its second CVD program, is a research stage technology focused on molecular targets of vascular inflammation. ReVas is its third cardiovascular program dedicated to the research and development of therapeutic compounds to be used with medical devices and biomaterials for the local non-systemic treatment of CVD, in particular restenosis. NexVas Alzheimer’s Disease is a discovery stage technology for the development of drugs that enhance ApoA-I for stabilization and regression of Beta Amyloid Plaque. (Source: ARS)
PharmaGap Inc. is a development stage company, principally engaged in drug development and out-licensing of drug compounds. It is a biotechnology company with the main focus on designing and developing therapeutic drugs for the treatment of cancer and other human diseases associated with the human Protein Kinase C enzyme (PKC). Using its drug development platform, the Company is developing a pipeline of compounds targeting PKC. PKC is expressed in abnormal levels in many types of cancer and other diseases, such as diabetes. As of December 31, 2007, the Company’s lead drug compound, PhGa1, was in the pre-clinical testing stage, and had shown in vitro and in vivo efficacy in selected cancer types. (Source: ARS)
Neurochem's strategic plan focuses on the research, development and commercialization of products to provide innovation health solutions to patients suffering from serious diseases. With promising drug candidates currently in clinical trials and with expanding drug development programs, Neurochem is a company coming of age. The Company was founded in 1993 by the technology transfer office of Queen's University, Parteq Research and Development Innovations, in Kingston, Ontario, Canada, to develop and commercialize small organic molecules. These molecules, discovered by lead researchers at the university, form the basis of Neurochem's unique technology. Today, Neurochem is proud to count on the dedication of a team of close to 200 researchers, management and staff. To advance the development of its breakthrough technologies through clinical trial and commercialization phases, Neurochem has entered and continues to negotiate a variety of international R&D agreements, partnerships, collaborations and contracts with renowned scientists, researchers, academic institutions, pharmaceutical companies and contract research organizations, while maintaining the full ownership of its therapeutic rights. Our site is best viewed with IE4+ at a resolution of 1024×768.
Cytochroma Inc. is a development stage specialty pharmaceutical company focused on the treatment and prevention of disorders related to Vitamin D insufficiency. The Company has a portfolio of therapeutics with lower development risk for the indications of Vitamin D insufficiency and for secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). Cytochroma's pipeline products address significant unmet medical needs with a target market that is expected to grow significantly, reaching more than $1.2 billion annually by 2010 in North America alone. Cytochroma's understanding of the biology of Vitamin D combined with our management's experience in the development and commercialization of Vitamin D therapies, uniquely positions us to positively impact the outcomes of CKD patients suffering from diseases related to Vitamin D insufficiency.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory